New Agents for Taxol-Resistant Ovarian Carcinoma

Abstract

Taxol resistance is an important issue in relapsing% ovarian cancer. Two approaches to address this resistance include the use of drug copolymers and drug targeting. In this proposal, paclitaxel covalently coupled to backbones of poly(L-glutamic) acid (non-targeted) or hyaluronic acid (CD44 targeted) as prodrugs will be evaluated in CD44 over-expressing human ovarian carcinoma i.p. (orthotopic) xenografts. We have now documented both the greatly reduced toxicity as well as the anti-tumor efficacy of a lead formulation of HA-TXL compared to Taxol in human ovarian tumor (NMP-1)-bearing nude mice. Additional studies will attempt to develop a superior HA-TXL formulation and compare its toxicity and efficacy to PGA-TXL, which is already in clinical trials.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2004
Accession Number
ADA428544

Entities

People

  • Jim Klostergaard

Organizations

  • The University of Texas MD Anderson Cancer Center

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Availability
  • Biomedical Research
  • Classification
  • Electronic Mail
  • Information Operations
  • Instructions
  • Maryland
  • Monitoring
  • Resistance
  • Security
  • Universities

Fields of Study

  • Biology
  • Medicine

Readers

  • Oncology (Cancer Research).

Technology Areas

  • Microelectronics